ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Medications for Weight Loss: The New Satiety Hormones

Scripps Health

K. Fujioka

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

Weightloss in Menopause

Susan Brian

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Tirzepatide Updates

Diana Isaacs

Effects of Low Calorie and Alternative Sweeteners Across the Lifespa…

Keck School of Medicine of USC

M. Goran

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Practical Ways to Achieve Targets in Diabetes Care

S. Nissen

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Tirzepatide for Type 2 Diabetes

Diana Isaacs

Obesity: New Understanding and Treatments

Norman Lepor

Hypertension Management: The Ongoing Needs and Latest Science

Cleveland Clinic Heart, Vascular and Thoracic Institute

A. Sarraju

Type 2 Diabetes - Medical Management

Michigan Medicine

A. Rothberg

Mounjaro Update 2024

Susan Brian